Pilot Study of Hydroxychloroquine for the Treatment of AIMSS

Part of paid clinical trials in Indianapolis, Indiana.

Sponsor
Indiana University
Study ID
NCT07825454
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS)
  • Breast Cancer
  • Joint Pain

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Hydroxychloroquine Sulfate (HCQ) — DRUG
    Drug: Hydroxychloroquine sulfate Dose: 400 mg orally once daily Duration: 12 weeks

Study Details

The purpose of this study is to evaluate the effectiveness of hydroxychloroquine sulfate (a type of drug commonly used to treat joint pain caused by inflammation, swelling) in reducing joint pain associated with Aromatase Inhibitor Associated Musculoskeletal Syndrome (AIMSS) for patients with breast cancer.

Key Dates

First listed
Sep 17, 2026
Start date
Sep 30, 2026
Status verified
Sep 2026
Primary completion
Dec 31, 2029
Completion
Dec 31, 2029

Study Design

Enrollment
35 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Hydroxychloroquine sulfate
    Hydroxychloroquine sulfate, 400 mg orally once daily

Primary Outcome Measure

To evaluate the efficacy of hydroxychloroquine [ Time Frame: Day 1 and Week 12 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Indiana University Melvin and Bren Simon Comprehensive Cancer CenterIndianapolisIndiana46202
Niraj Shah, MS
317-278-3420
Tarah Ballinger, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Indianapolis, IN

By condition

Related Studies